gastrointestinal cancer

The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.

Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.

The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

This Week in Science

In Science this week: immunogenic mutations in GI cancers, and more.

The research may lay the groundwork for a noninvasive test for GI or other types of cancer without prior knowledge of which organ is affected.

The agreement expands the partners' alliance to include additional diseases within the gastrointestinal tract.

In GIST tumors lacking genetic mutations, researchers uncover an epimutation affecting a gene promoter.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.